MeiraGTx reports preclinical gene therapy data showing retinal protection in dry AMD models

• MeiraGTx will present four research posters at the ESGCT congress and NEALS annual meeting, both scheduled for October 27-30, 2026.
• AAV-NRF2 protected retinal cells from oxidative damage in preclinical dry AMD models; results will be presented October 29.
• Optimized AAV-hUPF1 improved neuronal function in patient-derived cells and motor neuron survival in an ALS mouse model.
• The ALS findings, scheduled for presentation October 28, also include early expression studies supporting development of AAV-hCNTFRα.
• Additional ESGCT posters cover analytical methods intended to support gene therapy product characterization, quality control and future commercial licensing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270800PRIMZONEFULLFEED9853781) on October 27, 2026, and is solely responsible for the information contained therein.